Mallinckrodt forced to shutter ALS study testing its controversial Acthar gel
Mallinckrodt, the current maker of Acthar — a drug first developed in the 1950s — said on Tuesday said it was abandoning its quest to market the gel in patients with Lou Gehrig’s disease.
The company was testing the drug in a Phase II study designed to enroll 213 patients — when an independent data and safety monitoring board recommended axing the trial due to the lack of an efficacy signal, and pneumonia occurring at a higher rate in Acthar-treated patients.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.